PIKSci

PIKSci is a private biotechnology company developing novel therapeutics centered on PIKfyve inhibition, with an initial focus on cancer and particular emphasis on B-cell malignancies. Publicly available materials indicate the company is advancing small-molecule programs that target lysosomal biology and autophagy, and it has described broader interest in autoimmune disease and viral infection. The company has presented preclinical data on a lead candidate, PIK-001, for multiple myeloma and related hematologic cancers, and it also holds patent-protected triazolo-pyrimidine chemical matter associated with PIKfyve inhibition. PIKSci appears to be based in Toronto, Canada and remains privately held.